About this document
mRNA Cell Therapy for Autoimmunity by bmsproject062024 is a document available to read on EtoBox.
Cartesian Therapeutics is advancing mRNA cell therapies for autoimmune diseases, with key candidates Descartes-08 and Descartes-15 targeting conditions like myasthenia gravis and systemic lupus erythematosus. Descartes-08 has shown promising results in a Phase 2b trial, achieving significant improvements in patient responses and a favorable safety profile, supporting its progression to a Phase 3 study. The company maintains a strong financial position with approximately $220.9 million in cash resources to s
- Author
- bmsproject062024
- Language
- EN